Tazemetostat(TAZVERIK) is a novel EZH2 inhibitor that provides a new treatment pathway for patients with multiple refractory and recurrent diseases. It blocks the growth and spread of lesion cells by inhibiting the activity of EZH2 enzymes, especially in the treatment of epithelioid sarcoma and follicular lymphoma.
Tazemetostat(TAZVERIK) provides a new treatment path for patients with multiple refractory and recurrent diseases
Tazemetostat is a small molecule inhibitor against EZH2 enzyme, mainly used to treat refractory and recurrent epithelioid sarcoma and follicular lymphoma. It provides patients with new therapeutic options by inhibiting the activity of EZH2 enzymes and blocking the proliferation and spread of lesion cells.
The treatment principle of Tazemetostat
Tazemetostat selectively inhibits the activity of EZH2 enzymes and blocks the epigenetic regulation of lesion cells, thereby inhibiting the growth and spread of lesions. The inhibition of EZH2 enzymes is overexpressed in a variety of lesions, especially in epithelioid sarcoma and follicular lymphoma, and Tazemetostat provides new therapeutic pathways for these refractory diseases.
Tazemetostat's indications
Tazemetostat is suitable for non-completely resectable metastatic or locally advanced epithelioid sarcoma in children and adults aged 16 years and older. It is also used to treat recurrent or refractory follicular lymphoma, especially those carrying EZH2 mutations.
Tazemetostat has significant therapeutic effects, but patients should pay attention to its possible side effects and related precautions when using it.
How to use Tazemetostat?
The recommended dose of Tazemetostat is 800 mg twice daily, orally with oral administration with oral disposal until the disease progresses or unacceptable toxicity occurs. Patients should swallow the whole tablet when taking it, avoid cutting, crushing or chewing the tablets.
How to take Tazemetostat
Tazemetostat should be taken twice a day at 800 mg each time, oral can be taken with oral food. If you miss one dose or vomit after taking it, do not take it again, but you should continue to take the next dose according to the medication plan. Patients should monitor adverse reactions regularly during medication and adjust the dose according to the doctor's advice.
Dose adjustment
For patients with mild liver impairment, it is not recommended to adjust the dose of Tazemetostat. Dosage adjustments in patients with moderate or severe liver impairment have not been determined and should be used under the guidance of a doctor.
The usage and dosage of Tazemetostat need to be adjusted according to the specific situation of the patient, especially for patients with liver function impairment.
Side effects and precautions of Tazemetostat
Patients should regularly monitor adverse reactions during use to prevent possible serious side effects.
Common side effects
Common side effects of Tazemetostat include pain, fatigue, nausea, decreased appetite, vomiting, and constipation. Patients should regularly monitor these adverse reactions during medication use, and adjust the dose or suspend the medication if necessary according to the doctor's advice.
Things to note
Tazemetostat may increase the risk of secondary lesions. Patients should undergo regular examinations during use. Tazemetostat has embryonic-fetal toxicity. Pregnant women and women with reproductive potential should take effective contraception during use. Lactation women should avoid breastfeeding during use.
Tazemetostat is a prescription drug. Patients should strictly follow the doctor's instructions when using it, conduct regular reviews to prevent possible serious adverse reactions.
